MedTrace Logo

The Role of Affect Regulation and Self-presentation in the Expressive Writing Intervention

NCT00831727 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2016-05-12

No results posted yet for this study

Summary

The purpose of the present study is twofold. First, we will attempt to examine the role that emotion regulation and self-presentation play as potential moderators in the expressive writing paradigm. We hypothesize that expressive writing participants who demonstrate greater abilities to regulate their emotions at baseline will improve more on our outcome measures. We also hypothesize that those expressive writing participants who demonstrate higher levels of self-presentation at baseline will improve less on our outcome measures.

The second aim of the study has two related objectives. First, we will attempt to investigate whether the expressive writing intervention can increase and enhance an individual's emotion regulation abilities. Related to this, we will then go on to examine whether emotion regulation can be looked at as a potential mechanism of action in the expressive writing procedure. Related to these two objectives, we hypothesize that in comparison to the control group, participants in the expressive writing condition will show increases in their ability to regulate their emotions from baseline to four week follow up. Moreover, we predict that greater gains in emotion regulation abilities for the expressive writing participants will be significantly related to greater gains in outcome measures.

Conditions

  • Posttraumatic Stress Disorders

Interventions

BEHAVIORAL

Expressive Writing

Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing

BEHAVIORAL

Control

Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days

Sponsors & Collaborators

  • University of Toronto

    lead OTHER

Principal Investigators

  • Jeanne C Watson, Ph.D. · University of Toronto

  • Justin M Mattina, M.A. · University of Toronto

  • Jonathan J Danson, B.A. · University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00831727 on ClinicalTrials.gov